Central Pharmaceutical JSC No3
VN:DP3
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
49 800
62 700
|
| Price Target |
|
We'll email you a reminder when the closing price reaches VND.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Central Pharmaceutical JSC No3
Revenue
Central Pharmaceutical JSC No3
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Central Pharmaceutical JSC No3
VN:DP3
|
Revenue
â‚«422.5B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
8%
|
|
|
H
|
HaTay Pharmaceutical JSC
VN:DHT
|
Revenue
â‚«2.2T
|
CAGR 3-Years
11%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
10%
|
|
|
I
|
Imexpharm Corp
VN:IMP
|
Revenue
â‚«2.5T
|
CAGR 3-Years
18%
|
CAGR 5-Years
12%
|
CAGR 10-Years
10%
|
|
|
C
|
Cuu Long Pharmaceutical JSC
VN:DCL
|
Revenue
â‚«1.3T
|
CAGR 3-Years
23%
|
CAGR 5-Years
12%
|
CAGR 10-Years
6%
|
|
|
D
|
Dhg Pharmaceutical Joint-Stock Co
VN:DHG
|
Revenue
â‚«5T
|
CAGR 3-Years
4%
|
CAGR 5-Years
5%
|
CAGR 10-Years
3%
|
|
|
T
|
Traphaco JSC
VN:TRA
|
Revenue
â‚«2.6T
|
CAGR 3-Years
2%
|
CAGR 5-Years
7%
|
CAGR 10-Years
3%
|
|
Central Pharmaceutical JSC No3
Glance View
Central Pharmaceutical JSC No.3 engages in the manufacture and sale of pharmaceutical, cosmetic, and nutritious food. The company is headquartered in Haiphong, Hai Phong. The company went IPO on 2015-07-17. The firm's leading products include botanical medicine and other types of drugs, health supplements and cosmetics, among others. Besides, the Company partakes in the commerce of medical equipment and supplies, as well as the conduct of medical research.
See Also
What is Central Pharmaceutical JSC No3's Revenue?
Revenue
422.5B
VND
Based on the financial report for Sep 30, 2025, Central Pharmaceutical JSC No3's Revenue amounts to 422.5B VND.
What is Central Pharmaceutical JSC No3's Revenue growth rate?
Revenue CAGR 10Y
8%
Over the last year, the Revenue growth was 6%. The average annual Revenue growth rates for Central Pharmaceutical JSC No3 have been -11% over the past three years , -3% over the past five years , and 8% over the past ten years .